Designs for Vision has been appointed as distributor of the E-Eye intense pulsed light (IPL) device in Australia.
E-Eye, manufactured by E-Swin in France, was first introduced in Australia around five years ago. Approximately 200 devices are currently being used by optometrists and ophthalmologists across the country to treat the symptoms of dry eye disease and meibomian gland dysfunction.
Designs for Vision gaining distribution rights for E-Eye in Australia is excellent news for existing and prospective E-Eye customers.
We are really excited to have been appointed distributor – it’s a new chapter for our business and although it is a significant investment for us, knowing that the E-Eye has been supported with numerous clinical studies by pre-eminent researchers including Associated Professor Jennifer Craig in New Zealand, and that we have a strong existing customer base, is reassuring.
Customers who have been uncertain about where they can obtain product support can also now feel reassured.
Designs For Vision is one of the most respected suppliers to the Australian ophthalmic industry. We were established in 1978 and have strong expertise right across the country. Partnering with a professional organisation in E-Swin is a natural fit, and customers will now have convenient and fast access to consumables and expert technical support.
Designs for Vision will relaunch E-Eye at RANZCO Congress in Sydney in November and Petra Bruckmüller, President and Managing Director of E-Swin, will be at the Congress to speak with existing customers and others who are interested to find out more about the technology.
We will celebrate the re-launch with special introductory pricing until the end of 2019, so we encourage people to take advantage and stock up on consumables or purchase the unit itself at a special price.
Interested in learning more about the benefits of IRPL treatment, or want to talk about a deal? Call us now.
The affection of the lipid phase produced by these cells – the meibum – will lead to an excessive evaporation of tears, an unstable lacrymal film and an inflammatory reaction of the conjonctiva.
The result is an increase in vision disorders during long periods of short-distance tasks (work on computer screens…) with a feeling of “eye burning” stopping any visual work.
If this process accelerates, the discomfort becomes permanent creating a paradoxal tear increase; wearing contact lenses becomes impossible.
Anatomical modifications can occur with an atrophy of the meibomian glands orifices with episodical infections, sties, conjunctival secondary infections, chalazion and in more serious cases, apparition of micro-ulcerations of the epithelium cornea.
Meibomian gland dysfunction has been identified to be the main cause of dry-eye syndrome around the world.
This is the first report about Meibomian Gland Dysfunction (MGD) from the ARVO (the association for Research in Vision and Ophthalmology) conference organized in 2010. The gathering of more than 50 members included the most recognised ophthalmology and optometry experts around the globe.
Since then, an efficient treatment of the Meibomian Gland Dysfunction, radically different from existing treatments, has been developed and clinically tested with exceptional results.
The dry-eye syndrome is a common pathology affecting – depending on the areas – between 5 to 15% of the population with symptoms increasing with age. Conditions of a modern lifestyle (including working on computer screens, driving cars, artificial lights, air pollution, wearing eye contact lenses…) make dry-eye syndrome a more and more frequent nuisance.
Generally speaking, dry-eye conditions are a result of a lacrymal layer issue, either caused by insufficient tears or an excessive evaporation.
It is recognised that a large majority of cases are caused by the evaporation form, mainly due to an insufficiency of the external lipid layer of the lacrymal film secreted by the Meibomian glands.
The lacrymal film, necessary to the eye function, is made of 3 layers:
There are 80 meibomian cells located on the upper and lower eyelids.
These cells produce a fat phase, avoiding tear evaporation, adapting the tears to the irrigularities of the eye surface and a perfectly convex dioptre.
Lipids are made of polarised fat acids. Their fluidity is ensured by the body temperature. They are non-polarised on the surface, giving the stability of the lacrymal fluid and allowing the lubrification of the palpebral conjonctival plan. The contraction of the Riolan muscle allows the lacrymal film to spread out.
Everyday dysfunctional signs of patients generate multiple therapeutic treatments. Treatments currently available are mainly substitutions and are often insufficient to overcome the discomfort felt by patients.
E-EYE is a device that generates a new type of polychromatic pulsed light by producing perfectly calibrated and homogenously sequenced light pulses. The sculpted pulses are delivered under the shape of regulated train pulses. The energy, spectrum and time period are precisely set to stimulate the meibomian glands in order for them to return to their normal function.
E-EYE TREATMENT RESULTS
The efficiency is nearly constant on all forms of Meibomian Gland Dysfunctions.
On the other hand, it does not improve pathologies linked to aqueous or mucous phase or if there is a secondary infection that would need to be treated first.
Clinical studies have been conducted in France, New Zealand and China. These studies have shown:
3D animation movie showing operation mechanism of dry eye treatment using intense pulsed light technology device : E-Eye